Investors should monitor upcoming clinical data readouts in H2 2026, particularly combination trial initiations, which could validate BBOT's dual-pathway inhibition strategy and drive significant value. The strong cash runway reduces near-term dilution risk.
Price Chart
Executive Summary
BBOT, a clinical-stage oncology company, reported its fourth quarter and full year 2025 financial results alongside positive preliminary clinical data across its three RAS-pathway inhibitors. The company highlighted differentiated safety and efficacy profiles for BBO-8520, BBO-11818, and BBO-10203, with key data readouts expected in the second half of 2026. BBOT has a strong cash position of $425.5 million, providing runway into 2028.
Key Financial Metrics
Key Facts
- Preliminary clinical data show a 65% ORR for BBO-8520 monotherapy in KRASG12C NSCLC and a confirmed partial response in pancreatic cancer for BBO-11818, the first publicly disclosed panKRAS inhibitor response in PDAC.
- BBO-10203 demonstrated no hyperglycemia without HbA1c restrictions, supporting its potential in combination therapies.
- Cash, cash equivalents, and marketable securities totaled $425.5 million as of December 31, 2025, up from $155.6 million in 2024.
- R&D expenses increased to $38.1 million in Q4 2025 from $19.5 million in Q4 2024 due to advancing clinical programs.
- Net loss was $38.8 million in Q4 2025 vs. $19.7 million in Q4 2024; full-year net loss was $134.0 million in 2025 vs. $74.3 million in 2024.
- Company expects clinical readouts across all three programs in the second half of 2026 and plans to initiate internal combination trials later in 2026.
Financial Impact
Cash position increased by $269.8 million year-over-year, funding operations into 2028. R&D and G&A expenses rose significantly due to clinical advancement and post-SPAC operations.
Risk Factors
- Clinical data are preliminary; later-stage results may not confirm early efficacy or safety signals.
- Increased R&D spend may pressure margins if development timelines extend or trials fail.
- Competition from other KRAS and panKRAS inhibitors in development could limit market potential.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3250671 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 11, 2026 6w ago | EFFECT | $4.95 $3.31 | ▲ +33.13% | ▲ +35.00% | $2.64 (+46.67%) |
Sep 9, 2026 6w ago | EFFECT | $6.76 $3.44 | ▼ −49.07% | ▼ −51.27% | $2.64 (−60.92%) |
Aug 15, 2026 10w ago | Institutional Cluster | $9.04 $4.88 | ▲ +46.02% | ▲ +44.04% | $2.64 (+70.80%) |
Aug 11, 2026 10w ago | Press Release | $9.42 $5.52 | ▼ −41.40% | ▼ −39.50% | $2.64 (−71.97%) |
Jun 22, 2026 18w ago | 8-K | $7.50 $8.42 | ▲ +12.27% | ▲ +11.11% | $2.64 (−64.80%) |
May 12, 2026 23w ago | Press Release | $8.08 $7.46 | ▼ −7.67% | ▼ −7.06% | $2.64 (−67.33%) |
Apr 21, 2026 26w ago | Press Release | $8.87 $8.72 | ▼ −1.69% | ▼ −4.86% | $2.64 (−70.24%) |
Apr 20, 2026 27w ago | Press Release | $9.46 $8.75 | ▼ −7.51% | ▼ −12.42% | $2.64 (−72.09%) |
Mar 6, 2026 33w ago | Press Release | $10.42 $8.91 | ▼ −14.49% | ▼ −12.45% | $2.64 (−74.66%) |
Mar 5, 2026 33w ago | 8-K | $10.42 $8.91 | ▼ −14.49% | ▼ −12.45% | $2.64 (−74.66%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers